Moderna, Inc. (MRNA)
Healthcare · end-of-day data as of Oct 16, 2026
The average 12-month analyst price target for MRNA is $163.56, 25.0% below the last close of $218.01 on Oct 16, 2026; targets range from $79.96 to $309.13. Rating consensus: Hold.
Snapshot
- P/E—
- P/E vs sector—
- P/E vs own—
- Target upside-25.0%
- ConsensusHold
- Market cap$87.04B
- FCF yield-1.4%
- Insiders-$62.59M
- Earnings in21d
- News
Why it moved
Moderna, Inc. (MRNA) fell 7.8% on Oct 16, 2026.
The market (SPY) fell 1.1%; Healthcare stocks fell 0.6%. Most of the move is specific to MRNA.
6 stories on the day (30-day average 2.9).
- Why is Moderna down 10% on Friday?
- Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
- Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $218.01 · +703.3% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendbullish
- Sector▲ +16.0%
- MAs20▲ 50▲ 100▲ 200▲
- Above MAs4 of 4 above
- MA20×50—
- RSI62
- Support-37.3%
- Resistance—
- Off 52w high-7.8%
- Off ATH-55.0%
- 52w range$218.01
- Bollingerupper half
- MACD0.38
- ATR+7.7%
- Volume1.2x
Analyst price targets
7 firms with a target in the last 12 months · last close $218.01 · as of Oct 16, 2026
Strong buy 1 · Buy 4 · Hold 15 · Sell 2 · Strong sell 2
Revenue and free cash flow
Q2 FY2026: Revenue +2.1% year over year, free cash flow -388.3% of revenue, operating margin -562.1%.
| Q2 FY2026 | Jun 30, 2026 | $145M | -1.96 | -$563M | 35.9% | -562.1% | -539.3% |
| Q1 FY2026 | Mar 31, 2026 | $389M | -3.40 | -$692M | -145.5% | -356.8% | -345.2% |
| Q4 FY2025 | Dec 31, 2025 | $678M | -2.11 | $912M | 33.3% | -126.4% | -121.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.02B | -0.51 | -$880M | 0.8% | -25.6% | -19.7% |
| Q2 FY2025 | Jun 30, 2025 | $142M | -2.13 | -$922M | 16.2% | -638.7% | -581.0% |
| Q1 FY2025 | Mar 31, 2025 | $107M | -2.52 | -$1.16B | 15.9% | -981.3% | -907.5% |
| Q4 FY2024 | Dec 31, 2024 | $956M | -2.91 | $303M | 22.7% | -130.3% | -117.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.85B | 0.03 | -$1.72B | 72.3% | -3.8% | 0.7% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $499.74 | -1.8% | -10.4% | +14.0% | 29.1 | $127B | |
| 2 |  | $428.26 | 0.0% | 0.0% | +1.9% | 19.0 | $92.88B | |
| 3 | | $218.01 | -7.8% | -7.8% | -25.0% | — | $87.04B | |
| 4 |  | $790.74 | -0.7% | -7.2% | +8.7% | 19.6 | $81.41B | |
| 5 |  | $302.30 | +1.2% | -0.2% | +10.9% | 12.5 | $79.88B | |
| 6 |  | $231.83 | -0.9% | -52.8% | +61.5% | 39.2 | $31.02B | |
| 7 |  | $113.07 | -0.2% | -13.0% | +13.6% | 14.4 | $22.92B | |
| 8 |  | $72.57 | +0.1% | -0.1% | -7.0% | 62.6 | $11.38B |
Data as of Oct 16, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.